Item | Catalog # | Description | Quantity | Price (USD) | ||
---|---|---|---|---|---|---|
Plasmid | 27056 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $75 | Add to Cart | |
AAV1 | 27056-AAV1 | Virus (100 µL at titer ≥ 1×10¹³ vg/mL)and Plasmid.More Information | Add to Cart | |||
AAV2 | 27056-AAV2 | Virus (100 µL at titer ≥ 3×10¹² vg/mL)and Plasmid.More Information | Add to Cart | |||
AAV5 | 27056-AAV5 | Virus (100 µL at titer ≥ 1×10¹³ vg/mL)and Plasmid.More Information | Add to Cart | |||
AAV9 | 27056-AAV9 | Virus (100 µL at titer ≥ 1×10¹³ vg/mL)and Plasmid.More Information | Add to Cart | |||
AAV Retrograde | 27056-AAVrg | Virus (100 µL at titer ≥ 7×10¹² vg/mL)and Plasmid.More Information | Add to Cart |
This material is available to academics and nonprofits only.
This plasmid contains the human elongation factor-1a promoter.
For additional information please visit - http://www.optogenetics.org
Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO EYFP (#27056). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO EYFP plasmid DNA.
EF1a-driven, cre-dependent EYFP expression.These AAV preparations are suitable purity for injection into animals.Requestor is responsible for compliance withtheir institution"s biosafety regulations.Lentivirus is generally considered BSL-2. AAV isgenerally considered BSL-1, but may requireBSL-2 handling depending on the insert.Biosafety Guide
Visit our viral production page for moreinformation.
Using FLEX vectors in vivo: LoxP sites in FLEX plasmids are known to recombine during DNA amplification and viral vector production, which may result in a minority of Cre-activated (i.e., "flipped") viral vectors. Addgene has measured this occurs in 0.01-0.03% of viral vectors in our typical production protocol. This can lead to a small number of cells exhibiting Cre-independent transgene expression in vivo. To address this, we recommend titrating to find the optimal AAV dosage required for Cre-dependent transgene expression and function in vivo. This may include reducing the viral vector dosage in order to reduce the likelihood of Cre-independent expression.
Data submitted about 27056-AAV1 by requesting scientist(s):
Ready-to-use AAV2 particles produced from pAAV-Ef1a-DIO EYFP (#27056). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO EYFP plasmid DNA.
EF1a-driven, cre-dependent EYFP expression.These AAV preparations are suitable purity for injection into animals.Requestor is responsible for compliance withtheir institution"s biosafety regulations.Lentivirus is generally considered BSL-2. AAV isgenerally considered BSL-1, but may requireBSL-2 handling depending on the insert.Biosafety Guide
Visit our viral production page for moreinformation.
Using FLEX vectors in vivo: LoxP sites in FLEX plasmids are known to recombine during DNA amplification and viral vector production, which may result in a minority of Cre-activated (i.e., "flipped") viral vectors. Addgene has measured this occurs in 0.01-0.03% of viral vectors in our typical production protocol. This can lead to a small number of cells exhibiting Cre-independent transgene expression in vivo. To address this, we recommend titrating to find the optimal AAV dosage required for Cre-dependent transgene expression and function in vivo. This may include reducing the viral vector dosage in order to reduce the likelihood of Cre-independent expression.
Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO EYFP (#27056). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO EYFP plasmid DNA.
EF1a-driven, cre-dependent EYFP expression.These AAV preparations are suitable purity for injection into animals.Requestor is responsible for compliance withtheir institution"s biosafety regulations.Lentivirus is generally considered BSL-2. AAV isgenerally considered BSL-1, but may requireBSL-2 handling depending on the insert.Biosafety Guide
Visit our viral production page for moreinformation.
Using FLEX vectors in vivo: LoxP sites in FLEX plasmids are known to recombine during DNA amplification and viral vector production, which may result in a minority of Cre-activated (i.e., "flipped") viral vectors. Addgene has measured this occurs in 0.01-0.03% of viral vectors in our typical production protocol. This can lead to a small number of cells exhibiting Cre-independent transgene expression in vivo. To address this, we recommend titrating to find the optimal AAV dosage required for Cre-dependent transgene expression and function in vivo. This may include reducing the viral vector dosage in order to reduce the likelihood of Cre-independent expression.
Data submitted about 27056-AAV5 by requesting scientist(s):
Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO EYFP (#27056). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO EYFP plasmid DNA.
EF1a-driven, cre-dependent EYFP expression.These AAV preparations are suitable purity for injection into animals.Requestor is responsible for compliance withtheir institution"s biosafety regulations.Lentivirus is generally considered BSL-2. AAV isgenerally considered BSL-1, but may requireBSL-2 handling depending on the insert.Biosafety Guide
Visit our viral production page for moreinformation.
Using FLEX vectors in vivo: LoxP sites in FLEX plasmids are known to recombine during DNA amplification and viral vector production, which may result in a minority of Cre-activated (i.e., "flipped") viral vectors. Addgene has measured this occurs in 0.01-0.03% of viral vectors in our typical production protocol. This can lead to a small number of cells exhibiting Cre-independent transgene expression in vivo. To address this, we recommend titrating to find the optimal AAV dosage required for Cre-dependent transgene expression and function in vivo. This may include reducing the viral vector dosage in order to reduce the likelihood of Cre-independent expression.
Data submitted about 27056-AAV9 by requesting scientist(s):
Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-DIO EYFP (#27056). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO EYFP plasmid DNA.
EF1a-driven, Cre-dependent EYFP expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.Requestor is responsible for compliance withtheir institution"s biosafety regulations.Lentivirus is generally considered BSL-2. AAV isgenerally considered BSL-1, but may requireBSL-2 handling depending on the insert.Biosafety Guide
Visit our viral production page for moreinformation.
Using FLEX vectors in vivo: LoxP sites in FLEX plasmids are known to recombine during DNA amplification and viral vector production, which may result in a minority of Cre-activated (i.e., "flipped") viral vectors. Addgene has measured this occurs in 0.01-0.03% of viral vectors in our typical production protocol. This can lead to a small number of cells exhibiting Cre-independent transgene expression in vivo. To address this, we recommend titrating to find the optimal AAV dosage required for Cre-dependent transgene expression and function in vivo. This may include reducing the viral vector dosage in order to reduce the likelihood of Cre-independent expression.
Addgene正在为我们收集的200多个质粒提供克隆级DNA(cgDNA)。以这种格式可获得的质粒包括多种流行的质粒和具有高克隆潜力的主链。通过将这些质粒以cgDNA的形式提供,我们希望帮助希望从Addgene那里获得质粒后立即开始克隆的科学家-消除了当人们在细菌刺中接受质粒时所需的扩增和提取步骤,从而缩短了实验时间。